Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

Université Laval

$173,914.00

Development of plasma-based coating processes for medical devices with tailored-range bactericidal properties

EF 2021-22

Résumé
Central venous catheters (CVCs) are vital for many applications in medicine, especially for critical care and cancer patients. The use of CVC is associated with risk of microbial contamination in the form of a central venous catheter-related blood stream infection (CVC-BSI), which can occur during their implantation or manipulation. CVC-BSI represent a major global health care challenge. Prevention of CVC-BSI are based on biofilm prevention and on the release of antibacterial agents to overcome bacterial proliferation. The most common and successful approaches include bulk modification techniques or surface approaches, such as physical (plasma) or chemical (grafting by plasma, gamma radiation, corona or laser). In this light, the hereby presented project proposes the development of a procedure for the fabrication of an antiadhesive, antibacterial and hemocompatible coatings, based on plasma enhanced chemical vapour deposition (PECVD). The planned surface modification of implantable CVCs will provide a relevant advancement to tackle the expensive nosocomial infection problems, which are responsible for a relevant increase of the hospitalization costs and clinical complications, up to mortality rate of 17% in patients affected by a CVC-BSI, estimated at 40% in Brazil. The planned surface modification strategies foresee the controlled release of metallic ions, embedded in different proposed architectures of multifunctional thin films; they will be deposited on silicone surfaces, and they will be optimized for tubular geometries. The here proposed approach is based on a collaborative research and development strategy involving the Laboratory for Biomaterials and Engineering of Laval University, with its world-renowned expertise in biomedical material and plasma surface treatments, Plasmionique Inc., an established Canadian company, devoted to plasma processes for industrial and research purposes, and IBEG, the leader catheters manufacturer in Brazil. The presented workplan foresees the participation of a network of clinicians, industrials and academic collaborators, to maximize the final impact on the introduced innovation element of CVC-BSI on the Canadian and global market.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
549867-2020
Name nom
Mantovani, Diego
Department département
Génie des mines, métallurgie et matériaux
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2020
Award amount
173914
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Installment
inst:2
Partie
1
Nb partie
3
Application title
Development of plasma-based coating processes for medical devices with tailored-range bactericidal properties
Keyword
NSERC
Application summary
Central venous catheters (CVCs) are vital for many applications in medicine, especially for critical care and cancer patients. The use of CVC is associated with risk of microbial contamination in the form of a central venous catheter-related blood stream infection (CVC-BSI), which can occur during their implantation or manipulation. CVC-BSI represent a major global health care challenge. Prevention of CVC-BSI are based on biofilm prevention and on the release of antibacterial agents to overcome bacterial proliferation. The most common and successful approaches include bulk modification techniques or surface approaches, such as physical (plasma) or chemical (grafting by plasma, gamma radiation, corona or laser). In this light, the hereby presented project proposes the development of a procedure for the fabrication of an antiadhesive, antibacterial and hemocompatible coatings, based on plasma enhanced chemical vapour deposition (PECVD). The planned surface modification of implantable CVCs will provide a relevant advancement to tackle the expensive nosocomial infection problems, which are responsible for a relevant increase of the hospitalization costs and clinical complications, up to mortality rate of 17% in patients affected by a CVC-BSI, estimated at 40% in Brazil. The planned surface modification strategies foresee the controlled release of metallic ions, embedded in different proposed architectures of multifunctional thin films; they will be deposited on silicone surfaces, and they will be optimized for tubular geometries. The here proposed approach is based on a collaborative research and development strategy involving the Laboratory for Biomaterials and Engineering of Laval University, with its world-renowned expertise in biomedical material and plasma surface treatments, Plasmionique Inc., an established Canadian company, devoted to plasma processes for industrial and research purposes, and IBEG, the leader catheters manufacturer in Brazil. The presented workplan foresees the participation of a network of clinicians, industrials and academic collaborators, to maximize the final impact on the introduced innovation element of CVC-BSI on the Canadian and global market.